{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:43:05Z","timestamp":1764240185120},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00482-018-0333-3","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T03:20:36Z","timestamp":1539141636000},"page":"464-467","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Post-Zoster-Neuralgie des linken Trigeminusastes V1"],"prefix":"10.1007","volume":"32","author":[{"given":"K.\u2011U.","family":"Kern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schwickert-Nieswandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"333_CR1","unstructured":"Fachinformation Qutenza. Stand Mai 2017. Online verf\u00fcgbar unter www. fachinfo.de. Abgerufen am 18. Mai 2018."},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/0333102414550107","volume":"35","author":"C Gaul","year":"2015","unstructured":"Gaul C, Resch S (2015) Application of the capsaicin 8\u202f% cutaneous patch in neuropathic pain of the head and face: a case series. Cephalalgia 35:545\u2013550","journal-title":"Cephalalgia"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0885-3924(03)00065-4","volume":"25","author":"N Harden","year":"2003","unstructured":"Harden N, Cohen M (2003) Unmet needs in the management of neuropathic pain. J\u00a0Pain Symptom Manage 25:S12\u201317","journal-title":"J. Pain Symptom Manage."},{"key":"333_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","volume":"371","author":"RW Johnson","year":"2014","unstructured":"Johnson RW, Rice AS (2014) Clinical practice. Postherpetic neuralgia. N\u00a0Engl J Med 371:1526\u20131533","journal-title":"N Engl J Med"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00482-015-0065-6","volume":"29","author":"KU Kern","year":"2015","unstructured":"Kern KU, Weiser T (2015) Topisches Ambroxol zur Behandlung neuropathischer Schmerzen. Eine erste klinische Beobachtung. Schmerz 29:632\u2013640","journal-title":"Schmerz"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/PPA.S76506","volume":"10","author":"M Laklouk","year":"2016","unstructured":"Laklouk M, Baranidharan G (2016) Profile of the capsaicin 8\u202f% patch for the management of neuropathic pain associated with postherpetic neuralgia: safety, efficacy, and patient acceptability. Patient Prefer Adherence 10:1913\u20131918","journal-title":"Patient Prefer Adherence"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/AJP.0b013e31829a4ced","volume":"30","author":"J Mou","year":"2014","unstructured":"Mou J, Paillard F, Turnbull B et\u00a0al (2014) Qutenza (capsaicin) 8\u202f% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain 30:286\u2013294","journal-title":"Clin J Pain"},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10194-012-0467-0","volume":"13","author":"J Sayanlar","year":"2012","unstructured":"Sayanlar J, Guleyupoglu N, Portenoy R et\u00a0al (2012) Trigeminal postherpetic neuralgia responsive to treatment with capsaicin 8\u202f% topical patch: a\u00a0case report. J\u00a0Headache Pain 13:587\u2013589","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"333_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1086\/522152","volume":"197","author":"K Schmader","year":"2008","unstructured":"Schmader K, Gnann JW Jr., Watson CP (2008) The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J\u00a0Infect Dis 197(Suppl 2):207\u2013215","journal-title":"J Infect Dis"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/pme.12143","volume":"14","author":"T Wagner","year":"2013","unstructured":"Wagner T, Poole C, Roth-Daniek A (2013) The capsaicin 8\u202f% patch for neuropathic pain in clinical practice: a\u00a0retrospective analysis. Pain Med 14:1202\u20131211","journal-title":"Pain Med"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-018-0333-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-018-0333-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-018-0333-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:18:31Z","timestamp":1570648711000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-018-0333-3"}},"subtitle":["Erfolgreiche Therapie mit Capsaicin 8\u202f%\u2011Pflaster"],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s00482-018-0333-3","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"10 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.-U.\u00a0Kern war in den vergangenen 3\u00a0Jahren Berater f\u00fcr die Firmen Astellas, AstraZeneca, Betapharm, Bionorica, Boehringer Ingelheim, Gr\u00fcnenthal, Indivior, Kyowa Kirin, Mundipharma, Ratiopharm, Sanofi und Teva sowie als Referent f\u00fcr die Firmen Astellas, AstraZeneca, Boehringer Ingelheim Berlin Chemie, Genzyme, Gr\u00fcnenthal, Hexal, Indivior, Lilly, MSD und Mundipharma t\u00e4tig. M.\u00a0Schwickert-Nieswandt hielt Vortr\u00e4ge f\u00fcr die Firma ratiopharm. Die Kasuistik wurde redaktionell von der Agentur KW Medipoint, Bonn, und der Firma Gr\u00fcnenthal, Aachen, unterst\u00fctzt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}